CClinicalTrials.gg
WithdrawnNCT01980368Updated Mar 12, 2018

Tai Chi Easy in Treating Cancer Survivors With Peripheral Sensory Neuropathy

An interventional study of Educational Intervention and Exercise Intervention in Cancer Survivor and Peripheral Sensory Neuropathy, sponsored by Mayo Clinic. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-03-12.

Sponsored by Mayo Clinic · Not applicable, Interventional, and Supportive care

Why this study was withdrawn
No participants enrolled-slow accrual
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This pilot clinical trial studies how well Tai Chi Easy works in treating cancer survivors with peripheral sensory neuropathy. Tai Chi Easy is a simple and repetitive form of exercise that consists of movements with meditation and may improve peripheral neuropathy symptoms among cancer survivors.

Read the detailed description

PRIMARY OBJECTIVES:

I. Examine effects of Tai Chi Easy (TCEasy) exercise intervention on peripheral sensory neuropathy of cancer survivors who have chemotherapy compared with an educational control (EC) intervention.

OUTLINE: Patients are randomized to 1 of 2 groups.

GROUP I (TAI CHI EASY): Patients attend Tai Chi Easy class for 60 minutes once a week for 6 weeks. Patients also receive a DVD and exercise manual of Tai Chi Easy exercises and are encouraged to practice at home for 30 minutes most days per week for 6 weeks.

GROUP II (EDUCATIONAL CONTROL): Patients receive readings each week and attend a book club to discuss the readings for 60 minutes once a week for 6 weeks.

After completion of study, patients are followed up at 2 months.

02

Conditions studied

  • Cancer Survivor
  • Peripheral Sensory Neuropathy
03

In context

Peripheral Nervous System Diseases

1,003 studies on the registry are indexed under Peripheral Nervous System Diseases; 177 are open to participants now.

Browse Peripheral Nervous System Diseases studies →

Lead sponsor

Mayo Clinic is the lead sponsor of 3,218 studies on the registry; 670 are open to participants now.

Of its 445 completed or terminated interventional studies of FDA-regulated products, 313 (70%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • 1 month - 5 years following completion of cytotoxic chemotherapy treatment for any cancer, and are experiencing neuropathy
  • Self-report of >= 4 on the Peripheral Neuropathy Question

Exclusion criteria

Exclusion Criteria:

  • Recurrence of cancer or other active cancer
  • Severe cachexia, dizziness, bone pain, or severe nausea (as judged by the investigator)
  • Uncontrolled diabetes, untreated hypothyroidism
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Group I (Tai Chi Easy)

    Patients attend Tai Chi Easy class for 60 minutes once a week for 6 weeks. Patients also receive a DVD and exercise manual of Tai Chi Easy exercises and are encouraged to practice at home for 30 minutes most days per week for 6 weeks.

    Behavioral: Exercise Intervention · Other: Questionnaire Administration

  • Active comparator
    Group II (educational control)

    Patients receive readings each week and attend a book club to discuss the readings for 60 minutes once a week for 6 weeks.

    Other: Educational Intervention · Other: Questionnaire Administration

Interventions

  • OtherEducational Intervention

    Receive readings and attend book club

    Also known as: Education for Intervention, Intervention by Education, Intervention through Education, Intervention, Educational

  • BehavioralExercise Intervention

    Receive Tai Chi Easy class, DVD, and exercise manual

  • OtherQuestionnaire Administration

    Ancillary studies

06

What researchers measure

Primary outcomes

  1. Change in peripheral sensory neuropathy, assessed by Peripheral Neuropathy Question, European Organization for Research and Treatment of Cancer (EORTC)-30, EORTC-Chemotherapy-induced peripheral neuropathy-20, and the modified Total Neuropathy Score

    Will be assessed with a simple t-test of mTNS means. Additional analyses of factors assessed will similarly be conducted (and overall analysis of variance when combining outcome variable assessment at the three time points, and models of factor contribution with logistic regression if appropriate).

    Time frame: Baseline up to 2 months

Secondary outcomes

  1. Changes in anxiety assessed by POMS Total Mood Disturbance dimensions (tension-anxiety)

    Time frame: Baseline up to 2 months

  2. Changes in body mass index assessed by weight and height

    Will be measured directly using standardized protocols with medical-quality calibrated balance scales.

    Time frame: Baseline up to 2 months

  3. Changes in cognitive performance assessed by digit span and letter-number sequencing

    Time frame: Baseline up to 2 months

  4. Changes in depression assessed by Program Operations Manual System (POMS) Total Mood Disturbance dimensions (depression-dejection)

    Time frame: Baseline up to 2 months

  5. Changes in fatigue assessed by Fatigue Symptom Inventory

    Time frame: Baseline up to 2 months

  6. Changes in pain assessed by Medical Outcomes Study-Short Form 36

    Time frame: Baseline up to 2 months

  7. Changes in sleep quality assessed by Pittsburgh Sleep Quality Index and actigraph

    Time frame: Baseline up to 2 months

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 12, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01980368
Lead sponsor
Mayo Clinic
Collaborators
National Cancer Institute (NCI)
Responsible party
Sponsor
First posted
Nov 11, 2013
Start date
Aug 2013
Primary completion
Jan 18, 2017
Completion
Jan 18, 2017
Last update
Mar 12, 2018

Study contacts

Donald Northfelt
principal investigator · Mayo Clinic
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion